Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schwarz Neupro "approvable"

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Schwarz' early-stage Parkinson's treatment Neupro (rotigotine transdermal system) is "approvable" pending submission of "additional analyses and summaries from the existing database," the firm announces March 1. "We anticipate responding to the action letter within six months," the company says. FDA's decision on the new molecular entity comes after the agency extended its user fee date by 90 days (1Pharmaceutical Approvals Monthly December 2005, p. 5). Schwarz plans to submit an sNDA for advanced Parkinson's by the end of 2006; Phase III results in restless legs syndrome are expected in the first quarter of 2007...

You may also be interested in...

Pfizer, Allergan And Schering NMEs Receive Second “Approvable” Letters

Pfizer’s anidulafungin received a second “approvable” letter Nov. 25 for treatment of esophageal candidiasis, FDA said.

QUOTED. 21 April 2021. Nicholas McQuaid.

A patient recruiter got 10 years in prison for his role in a scheme to convince seniors to get unneeded and expensive genetic tests. Nicholas McQuaid, acting assistant attorney general of the Justice Department’s Criminal Division, discussed the case.

Is The US FDA At A Tipping Point?

Wall Street is worried that a cluster of recent negative regulatory events means tougher reviews going forward. That concern is probably overdone, but a year into the COVID pandemic is a good time to take stock of how FDA is doing.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts